Q2 2024 |
51 |
$868M |
$0 |
$0 |
|
IDYA, ARGX, MRUS, RVMD, GPCR
|
New Holdings |
8/27/2024, 05:11 PM |
Q2 2024 |
51 |
$868M |
+$448M |
-$429M |
+$19M |
IDYA, ARGX, MRUS, RVMD, GPCR
|
13F-HR |
8/14/2024, 01:38 PM |
Q1 2024 |
50 |
$947M |
+$433M |
-$433M |
-$549K |
IDYA, IMCR, IMVT, OCUL, SRPT
|
13F-HR |
5/15/2024, 04:10 PM |
Q4 2023 |
47 |
$899M |
+$329M |
-$319M |
+$9.74M |
CYTK, IDYA, APLS, ARGX, OLMA
|
13F-HR |
2/14/2024, 03:35 PM |
Q3 2023 |
52 |
$701M |
+$222M |
-$221M |
+$1.82M |
IMVT, IDYA, OLMA, RCKT, CYTK
|
13F-HR |
11/14/2023, 09:25 AM |
Q2 2023 |
50 |
$724M |
+$179M |
-$263M |
-$84M |
APLS, CYTK, IMVT, IDYA, SRPT
|
13F-HR |
8/14/2023, 09:40 AM |
Q1 2023 |
43 |
$699M |
+$145M |
-$204M |
-$58.8M |
APLS, IDYA, CYTK, IMVT, ISEE
|
13F-HR |
5/15/2023, 10:19 AM |
Q4 2022 |
40 |
$854M |
+$203M |
-$178M |
+$24.7M |
IDYA, APLS, CYTK, IMVT, ALLK
|
13F-HR |
2/14/2023, 10:17 AM |
Q3 2022 |
38 |
$801M |
+$222M |
-$147M |
+$74.3M |
APLS, CYTK, IDYA, VTYX, DSGN
|
13F-HR |
11/14/2022, 01:12 PM |
Q2 2022 |
32 |
$545M |
+$146M |
-$257M |
-$111M |
CYTK, APLS, IDYA, DSGN, SRPT
|
13F-HR |
8/15/2022, 10:59 AM |
Q1 2022 |
47 |
$771M |
+$242M |
-$291M |
-$49M |
CYTK, ALXO, APLS, DSGN, NBIX
|
13F-HR |
5/16/2022, 10:50 AM |
Q4 2021 |
66 |
$970M |
+$299M |
-$500M |
-$201M |
ALXO, CYTK, DSGN, BCYC, APLS
|
13F-HR |
2/14/2022, 05:05 PM |
Q3 2021 |
57 |
$1.38B |
+$489M |
-$259M |
+$231M |
ALXO, OLMA, DCPH, BCYC, DYN
|
13F-HR |
11/15/2021, 01:44 PM |
Q2 2021 |
57 |
$1.17B |
+$460M |
-$160M |
+$299M |
ALXO, OLMA, DSGN, VERV, DYN
|
Restatement |
8/17/2021, 04:22 PM |
Q1 2021 |
53 |
$1.02B |
+$396M |
-$309M |
+$86.9M |
ALXO, OLMA, DSGN, DYN, TIL
|
13F-HR |
5/17/2021, 04:23 PM |
Q4 2020 |
58 |
$1.15B |
+$426M |
-$400M |
+$25.9M |
ALXO, OLMA, NKTX, FMTX, TGTX
|
13F-HR |
2/16/2021, 04:36 PM |
Q3 2020 |
46 |
$781M |
+$541M |
-$257M |
+$283M |
ALXO, KROS, NKTX, FMTX, GBT
|
Restatement |
11/17/2020, 03:14 PM |
Q2 2020 |
46 |
$500M |
+$418M |
-$199M |
+$219M |
FMTX, RETA, CLDX, RNA, RPTX
|
13F-HR |
8/14/2020, 12:23 PM |
Q1 2020 |
40 |
$260M |
+$154M |
-$193M |
-$39.8M |
ABBV, SRPT, MYOK, MRNA, ASND
|
13F-HR |
5/15/2020, 11:32 AM |
Q4 2019 |
38 |
$353M |
$0 |
$0 |
|
MRTX, SRPT, ASND, AMRN, APLS
|
13F-HR |
2/14/2020, 09:27 AM |